A
Alan Ashworth
Researcher at University of California, San Francisco
Publications - 589
Citations - 82138
Alan Ashworth is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 134, co-authored 578 publications receiving 72089 citations. Previous affiliations of Alan Ashworth include Imperial College London & Papworth Hospital.
Papers
More filters
Journal ArticleDOI
Erratum: Identification of the breast cancer susceptibility gene BRCA2
Richard Wooster,Graham R. Bignell,Jonathan Lancaster,Sally Swift,Sheila Seal,Jonathan Mangion,N. Collins,Simon G. Gregory,Curtis Gumbs,Gos Michlem,Rita Barfoot,Rifat Hamoudi,Sandeep Patel,Catherine M. Rice,Patrick J. Biggs,Yasmin Hashim,Amanda Smith,Frances Connor,Adelgeir Arason,Julius Gudmundsson,David Ficenec,David P. Kelsell,D Ford,Patricia N. Tonin,D. Timothy Bishop,Nigel K. Spurr,Bruce A.J. Ponder,Rosalind A. Eeles,Julian Peto,Peter Devilee,Cees J. Cornelisse,Henry T. Lynch,Steven A. Narod,Gilbert M. Lenoir,Valdgardur Egilsson,Rosa Bjork Barkadottir,Douglas F. Easton,David R. Bentley,P. Andrew Futreal,Alan Ashworth,Michael R. Stratton +40 more
Journal ArticleDOI
CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members.
Eirini Trompouki,Eudoxia Hatzivassiliou,Theodore Tsichritzis,Hannah Farmer,Alan Ashworth,George Mosialos +5 more
TL;DR: Results indicate that CYLD is a negative regulator of the cytokine-mediated activation of NF-κB that is required for appropriate cellular homeostasis of skin appendages.
Journal ArticleDOI
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C.C. Fong,Timothy A. Yap,D. S. Boss,Craig P. Carden,Marja Mergui-Roelvink,Charlie Gourley,Jacques De Greve,Jan Lubinski,Susan Shanley,Christina Messiou,Roger A'Hern,Andrew Tutt,Alan Ashworth,John F. Stone,James Carmichael,Jan H.M. Schellens,Johann S. de Bono,Stan B. Kaye +17 more
TL;DR: Olaparib has antitumor activity in BRCA1/2 mutation ovarian cancer, which is associated with platinum sensitivity, a significant association between the clinical benefit rate and platinum-free interval across the platinum-sensitive, resistant, and refractory subgroups.
Journal ArticleDOI
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards,Rachel Brough,Christopher J. Lord,Rachael Natrajan,Radost Vatcheva,Douglas A. Levine,Jeff Boyd,Jorge S. Reis-Filho,Alan Ashworth +8 more
TL;DR: It is shown that resistance to PARP inhibition can be acquired by deletion of a mutation in BRCA2, and new BRCa2 isoforms were expressed in the resistant lines as a result of intragenic deletion of the c.6174delT mutation and restoration of the open reading frame (ORF).
Journal ArticleDOI
A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
TL;DR: Tumors with compromised ability to repair double-strand DNA breaks by homologous recombination, including those with defects in BRCA1 and BRCa2, are highly sensitive to blockade of the repair of DNA single-Strand breaks via the inhibition of the enzyme poly(ADP) ribose polymerase, providing the basis for a novel synthetic lethal approach to cancer therapy.